[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Casa di Cura IGEA\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":112},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100632722","exercises-for-rehabilitation-of-cognition-and-lifestyle-enhancement-in-patients-with-mild-cognitive-impairment-100632722",false,"NCT07517380","Exercises for Rehabilitation of COgnition and Lifestyle Enhancement in Patients With Mild Cognitive Impairment","Sviluppo di un Intervento di Riabilitazione Cognitiva Applicabile e Sostenibile Nella Pratica Clinica Per i Pazienti Con Mild Cognitive Impairment","ERCOLE","Inclusion Criteria:\n\n* Diagnosis of MCI according to the diagnostic criteria of Petersen (2004) and Winblad et al. (2004) and, if applicable (i.e., MCI due to AD), according to those of Albert and colleagues (2011).\n* Self-reported basic skills in using technological devices, or access to a close person able to provide assistance.\n* Willingness of the patient to report, during the study period, any changes in the dosage of psychotropic drugs or other medications that may affect cognition, such as anticholinergics, opioids, benzodiazepines, antidepressants, muscle relaxants, and antiepileptics.\n\nExclusion Criteria:\n\n* Parkinson's disease.\n* Linguistic single-domain MCI (suspected onset of primary progressive aphasia).\n* Other neurological conditions potentially associated with cognitive impairment (e.g., previous stroke or traumatic brain injury).\n* Significant laboratory abnormalities potentially associated with cognitive impairment (e.g., low levels of vitamin B12 or folate, or values indicative of thyroid disorders).\n* Primary psychiatric disorders.\n* Alcohol or substance use disorder in the previous 10 years.\n* Severe behavioral disturbances limiting group participation.\n* Hearing or visual impairments that may interfere with assessment or treatment.\n* Medical conditions that may interfere with completion of the study.\n* Exposure, during the study period, to other neuropsychological rehabilitation interventions.\n* Patient's refusal to sign the informed consent.","ALL","50 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","Mild Cognitive Impairment (MCI) is a clinical condition with a heterogeneous etiology and clinical course characterized by objective cognitive deficits not severe enough to cause clear functional limitations or to warrant a diagnosis of dementia. Since MCI represents a risk factor for progression to various forms of dementia, timely preventive intervention is essential, although outpatient cognitive rehabilitation for this population is still limited by issues related to service accessibility.\n\nThis study aims to investigate the effectiveness of a multimodal group cognitive rehabilitation intevention designed to be accessible for patients with MCI and sustainable in clinical practice.\n\nThe primary objective of the study is to evaluate the effects of the intervention on cognitive, behavioural, and functional profile of patients with MCI, compared with an active control group. Outcome measures will be collected for all participants at T0 (baseline), T1 (after 12 weeks of intervention), and T2 (3 months after the end of the intervention and approximately 6 months from baseline), in order to assess both short-term and long-term effects of the intervention. The secondary objective is to explore the relationship between changes in outcome measures in the experimental group following the intervention and patients' demographic and clinical characteristics, with the aim of identifying potential predictors of a greater response to the intervention. Treatment accessibility, which guided the study design, will be evaluated though dropout and attendance rates, use of the provided tools and responses to the final satisfaction questionnaire.\n\nThe experimental group will receive a multimodal cognitive rehabilitation intervention, including (a) a multi-domain cognitive training and (b) a lifestyle intervention, consisting of psychoeducational sessions on neuroprotective factors and supported by the use of a web-based application accessible via computer and tablet. The intervention program will be delivered in small groups, with two 60-minute sessions per week over 12 weeks. The intervention was designed to enhance accessibility and sustainability by limiting intervention intensity and duration, using technology, and delivering group-based rehabilitation in groups that are not highly homogeneous. This approach is expected to result in a better cost-benefit balance and greater transferability to clinical practice. The control group will receive an informational booklet on neuroprotective factors, including practical daily-life recommendations to reduce risk profiles.\n\nForty patients with MCI and their informants will be recruited and randomly assigned to the experimental or control group. Participants in the experimental group will be further divided into small subgroups based on the presence of memory impairment.",[27],"Mild Cognitive Impairment (MCI)",[29,30,31,32,33,34,35,36],"Lifestyle Intervention","Cognitive Training Intervention","Non-pharmacological Intervention","Multicomponent Intervention","Group Cognitive Training Intervention","Multimodal Intervention","Digital Health Intervention","Randomized Controlled Trial","RECRUITING","2026-04-01",{"date":40,"type":41},"2026-04-08","ACTUAL",{"date":43,"type":41},"2026-02-16",{"date":45,"type":21},"2027-05",{"name":47,"class":48},"Casa di Cura IGEA","OTHER",2,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":17,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100588408","validation-of--synuclein-modifications-in-parkinsons-disorder-evolution-100588408","NCT06941012","Validation of α-synuclein Modifications in Parkinson's dIsoRder Evolution","Validation of α-synuclein Modifications in Parkinson's dIsoRder Evolution (VaMPiRE)","VaMPiRE","Inclusion Criteria:\n\n* • For PD subjects\n\n  * PD diagnosis according to MDS-UPDRS criteria and Hoehn and Yahr scale between I-IV (MED ON) for PD subjects\n  * Willing to participate. Participation is always voluntary.\n  * Willing and able to provide written informed consent to participate in the study or having a legal representative responsible for signing; the participant (or the legal representative) must understand the purpose, methods, and all information regarding the study.\n  * For non-PD subjects\n  * Normal neurological examination findings.\n  * Medical record (recent and remote medical history) available and reviewable by clinicians during the entire study period.\n  * Willing and able to provide written informed consent to participate in the study\n\nExclusion Criteria:\n\n* • For PD and non-PD subjects\n\n  * Clinically significant and severe cognitive decline and\u002For intellectual disability which can lead to impairment not caused by Parkinson's disease or any other disease that could better explain the patient's symptoms; The exclusion criteria involve neurological and neurodevelopmental disorders including disorders of the brain, spinal cord, peripheral nerve, and muscle (e.g. cerebral palsy, epilepsy \\[seizure disorders\\], stroke, intellectual disability, moderate to severe developmental delay, muscular dystrophy, or spinal cord injury).\n  * Fever (Temperature 38.0 °C (tympanic)).\n  * Acute infection (such as Flu, COVID-19) which could debilitate the patient and affect the data.\n  * Individuals with concurrent infections requiring systemic antimicrobial and\u002For antiviral therapy at the pre-dose examinations (e.g. HepC, HIV, TB).\n  * Life-threatening co-existing disease with life expectancy, which could lead to premature dropout.\n  * Any other neurological or systemic conditions that could confound results.",true,"18 Years","85 Years",{"count":62,"type":21},1200,"OBSERVATIONAL","Parkinson's disease (PD) presents a complex challenge due to its progressive neurodegenerative nature, affecting various bodily systems. Despite decades of research, understanding its onset and progression remains unclear, complicating early diagnosis and treatment. Recent advances in PD pathophysiology suggest promising treatments to slow disease progression, yet reversing cellular degeneration remains elusive. With novel therapies emerging, the need for early detection tools is urgent. However, validated biomarkers for PD diagnosis are lacking, relying on subjective scales like Hoehn and Yahr or costly medical imaging techniques. The accumulation of misfolded α-Synuclein (α-Syn) proteins in PD pathology has sparked interest, but defining diagnostic roles requires further investigation. Recent findings of α-Syn in neuronal-derived extracellular vesicles (NDEVs) from PD patients suggest a potential for novel diagnostic methods. Our proposed project, VαMPiRE, aims to conduct a longitudinal study involving 600 PD and 600 non-PD participants using a cluster-adjusted case-control methodology, to explore α-Syn isoforms and related biomarkers in NDEVs for early PD detection.\n\nWe plan to develop and validate an innovative in-vitro diagnostic (IVD) test capable of detecting PD's earliest stages and estimating disease prognosis and progression. Utilizing AI models to generate data analysis algorithms and collaboration with leading analytical laboratories and IVD manufacturers, we aim to ensure the reliability and feasibility of the developed prototype. Through consortium efforts, we envision licensing the generated intellectual property to drive the commercialization of our results.\n\nTwo round of blood sample extractions will be performed within a 24-month gap to PD participants and a single baseline for non-PD controls. All participants will be regularly followed up during this 24-month period to monitor disease evolution and treatment, and non-PD controls developing the disease will be part of a third cohort (expected to be around 24 subjects according to 4% incidence) that will confirm the sensitivity of the test in asymptomatic subjects. The unique aspect of the project is that we anticipate being able to detect theses 4% of non-PD participants that will go on to develop the disease, therefore demonstrating the value of these biomarkers to identify PD early.\n\nThe prototype will be validated for its discriminative capacity, using the first baseline set of PD and non-PD samples, and for its ability to detect the PD-progression comparing baseline and 24-months data plus blood samples.\n\nImproved early screening could allow for 270,000 new cases of PD to be detected earlier, improve the disease management of 9.4 M people currently diagnosed of PD and avoid losing a total of 5.8 million disability adjusted life years (DALYs) by 2028 leading also the development of better treatments.",[66],"Parkinson Disease (PD)",[68],"α-Synuclein","2026-02-27",{"date":71,"type":41},"2026-03-02",{"date":73,"type":41},"2025-05-12",{"date":75,"type":21},"2029-04-30",{"name":47,"class":48},4,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":58,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":89,"studyType":63,"phases":4,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},"100570006","italian-adaptation-and-validation-of-functional-and-behavioural-scales-for-subjective-cognitive-decline-mild-cognitive-impairment-and-mild-dementia-100570006","NCT06701630","Italian Adaptation and Validation of Functional and Behavioural Scales for Subjective Cognitive Decline, Mild Cognitive Impairment and Mild Dementia.","Functional and Behavioural Scales Validation in Italian.","ITA-VALI-DEM","Inclusion Criteria:\n\n* Age ≥ 60 years;\n* Availability of an informant\u002Fcaregiver, able to judge their functional abilities.\n\nFor neurologically unimpaired elderly:\n\n\\- Normal performance on the Mini Mental State Examination (Folstein et al. 1975; Foderaro et al., 2022).\n\nFor clinical groups: Conditions consistent with:\n\n* Subjective Cognitive Decline (Jessen et al., 2014)\n* Mild Cognitive Impairment (Winblad et al., 2004)\n* Mild Major Neurocognitive Disorder according (DSM-5-TR, APA, 2022).\n\nExclusion Criteria:\n\n* Refusal or inability to sign informed consent;\n* For the clinical groups: other neurological or psychiatric conditions that may explain the presence of cognitive difficulties.","60 Years",{"count":88,"type":21},390,"1 Day","The first aim of the observational study is the translation, cross-cultural adaptation and validation of functional and behavioral scales used in the diagnosis of neurodegenerative diseases, for which a formal version in Italian is not available at present. In particular, the study includes the following functional and behavioral scales: the Katz's index (Basic Activities of Daily Living, BADL), the Lawton and Brody's scale (Instrumental Activities of Daily Living, IADL), the Everyday Cognition questionnaire (E-Cog), the Neuropsychiatric Inventory Questionnaire (NPI-Q) for assessing the Behavioral and Psychological Symptoms of Dementia. Furthermore, a modified Italian version of the Functional Activities Questionnaire (FAQ), which integrates and updates the content of the original items (e.g., addressing the use of technologies, M-FAQ) will be used in the validation study.\n\nThe second aim is to evaluate the psychometric properties of the M-FAQ, the ECog, and the NPI-Q in terms of reliability and validity.\n\nThe third aim is to apply a Receiver Operating Characteristic (ROC) curve analysis to identify cut-offs of IADL, M-FAQ and ECOG to discriminate between different clinical groups (i.e., neurologically unimpaired elderly; Subjective Cognitive Decline, SCD; Mild Cognitive Impairment, MCI; mild Alzheimer's Disease, AD).\n\nNeurologically unimpaired elderly participants (over 60 years old) and participants with SCD, MCI, mild AD, and their caregivers\u002Finformants will undergo: i) administration of the translated versions of the scales; ii) administration of a Cognitive Reserve questionnaire. For SCD, MCI and AD participants, data from the clinical neuropsychological evaluation will also be collected, while paper-and-pencil psychometric tests to assess global cognitive functioning (Mini Mental State Examination) and logical-abstract reasoning (Raven's Colored Matrices) will be administered to the neurologically unimpaired participants.",[92,93,27,94],"Neurologically Unimpaired Elderly Participants","Subjective Cognitive Decline (SCD)","Major Neurocognitive Disorder",[96,97,98,99,100,101,102],"BADL and IADL","FAQ scale","ECog","NPI-Q","Italian adaptation","Validation","Functional and behavioral scales","2025-02-11",{"date":105,"type":41},"2025-02-13",{"date":107,"type":41},"2024-11-26",{"date":109,"type":21},"2026-11-30",{"name":47,"class":48},1,""]